IBA catalog GB int60p 10 v9 - IBA Molecular

PRODUCT 

CATALOGUE 

A complete 

palette in 

Nuclear 

Medicine 

Oncology 

Cardiology 

Neurology

INTERNATIONAL CATALOGUE ALOGUE 

2 | IBA | 

This is a comprehensive list of all products. 

Some products may not be available in your country, depending upon registration status. 

IBA reserves the right to modify the availability date of the products contained herein. 

Please contact your local distributor for further information. 

Approved SPC are available for download at: 

www.iba-molecular.com

Contents 

PRODUCT INDEX 

BY INDICATION .................................................................. 6 

BY NUCLIDE...................................................................... 8 

PRODUCT SPECIFICATIONS 

PET .................................................................................... 11 

Radiopharmaceuticals................................................... 11 

SPECT & THERAPY.............................................................. 15 

Radiopharmaceuticals................................................... 15 

Cold kits........................................................................ 27 

Accessories .................................................................. 37 

RADIOCHEMICALS ............................................................... 43 

PACKAGING ......................................................................... 45 

SERVICES ............................................................................ 49 

GENERAL INFORMATION 

COMMERCIAL INFORMATION ................................................. 52 

SCIENTIFIC AND TECHNICAL INFORMATION............................... 53 

UNITS ............................................................................. 55 

DEFINITIONS ..................................................................... 56 

NUCLIDE INDEX ................................................................. 57 

RADIOACTIVE DECAY TABLE .................................................. 59 

LOCATIONS AND CONTACTS .................................................. 63 

3 | IBA |



Product index 

By indication .................................................. 6 

By nuclide ...................................................... 8 

Offering a comprehensive range 

in Nuclear Medicine 

Fulfilling the needs of our customers can not be conceived in part only. Our product 

offering reflects our commitment to offer a complete radiopharmaceutical solution to 

nuclearists, from widespread to niche indications. With major applications in 

Oncology, Cardiology and Neurology, in PET, SPECT and Therapy, our range is one 

of the most comprehensive in the industry. 


DOPACIS ® 

NEUROLITE ® 

Thyroid 

CAPSION ® 

I-131-S-1 

I-131-S-2 

I-123-S-1 

I-123-S-2 

Sentinel nodes 

NANOCIS ® 


Lung 

PENTACIS ® 

PULMOCIS ® 

VENTIBOX 

VENTICIS ® II 

Liver 

PHYTACIS ® 

Bones 

CISNAF ® 

OSTEOCIS ® 

TECEOS ® 

QUADRAMET ® 

Products by indication 

Brain 


New active ingredient according to Spanish Royal Decree 1344/2007 

New product under intensive monitoring in United Kingdom 

Cardio-vascular system 

ANGIOCIS ® 

CARDIOGEN-82 

CARDIOLITE ® 

SERALB-125 

STAMICIS ® 

TL-201-S-1 

VASCULOCIS ® 

Adrenal glands/Kidneys 

NORCHOL-131 

PENTACIS ® 

RENOCIS ® 

Lymphatic system 

NANOCIS ® 

Joints (various sizes) 

ERMM-1 

RE-186-MM-1 

YMM-1 

Inflammation/ 

infection 

GA-67-MM-1 

SCINTIMUN ® 1 mg 

Others 

ELUMATIC ® III 

( 18 F)-FDG 

MIBG-131-D 

MIBG-131-T 

YTRACIS ®

PET 

Radiopharmaceuticals 

CISNAF ® p 12 

( 18F) Sodium Fluoride is used with positron 

emission tomography (PET). 

DOPACIS ® p 12 

( 18F) Fluorodopa is a solution used with 

positron emission tomography in neurology 

and oncology. 

FARNA FDG 1700 & 3000 p 13 

Medicinal product for diagnostic use only. 

Fludeoxyglucose ( 18F) is indicated for use with 

positron emission tomography. 

FDG-IBA P 13 


positron emission tomography in Oncology, 

Cardiology and Neurology. 

FLUCIS ® p 14 




FLUORSCAN 1700 & 3000 p 14 




SPECT and Therapy 


DIAGNOSIS 

ELUMATIC ® III p 17 

Sterile technetium ( 99mTc) generator. 

GA-67-MM-17 p 18 

Gallium ( 67Ga) citrate : 

- non-specific tumor imaging and/or localizing 

agent. 

- localization of inflammatory lesions. 

I-123-S-1 p 19 

Sodium iodide ( 123I) for labelling of 

radiopharmaceuticals. 

I-123-S-2 p 19 

Sodium iodide ( 123I) for functional and 

morphological study of the thyroid gland. 

MIBG-131-D p 21 

Iobenguane ( 131I) for calculation of a 

therapeutic iobenguane ( 131I) dose from a 

prior tracer-dose. 

NORCHOL-131 p 22 

6 - iodomethylnorcholesterol ( 131I) for 

investigation of adrenocortical diseases. 

SERALB-125 p 24 

Iodinated ( 125I) human serum albumin for 

determination of plasma and total blood 

volume, and examination of albumin turnover. 

TL-201-S-1 p 24 

Thallium ( 201Tl) chloride for myocardial 

scintigraphy. 

THERAPY 

CAPSION ® p 16 

Sodium iodide ( 131I) capsules for thyroid 

therapy. 

ERMM-1 p 18 

Erbium ( 169Er) citrate for isotopic radiation 

synovectomy (small size joints). 

I-131-S-1 p 20 

Oral sodium iodide ( 131I) for thyroid therapy. 

I-131-S-2 p 20 

Sodium iodide ( 131I) injection for thyroid 

diagnosis and therapy. 

MIBG-131-T p 21 

Radiation therapy of tumour-tissue that is 

capable of retaining metaiodobenzylguanidine. 

QUADRAMET ® p 22 

Samarium ( 153Sm)-EDTMP for the relief of 

bone pain in patients with multiple painful 

osteoblastic skeletal metastases which take 

up technetium ( 99mTc)-labelled bisphosphonates on bone scan. 

RE-186-MM-1 p 23 

Rhenium ( 186Re) sulphide for isotopic radiation 

synovectomy (medium size joints). 

YMM-1 p 25 

Yttrium ( 90Y) citrate colloidal suspension for 

isotopic radiation synovectomy (big size 

joints). 

YTRACIS ® p 25 

Yttrium ( 90Y) chloride radiopharmaceutical 

precursor solution for the radiolabelling of 

carrier molecules. 

Kits for radiopharmaceutical 

preparation 

ANGIOCIS ® p 28 

Kit for the preparation of stannous 

pyrophosphate used for in vivo labelling of 

Red Blood Cells with technetium ( 99mTc). CARDIOLITE ® p 28 

Kit for the preparation of technetium ( 99mTc) Sestamibi. Distributed on behalf of Lantheus 

Medical Imaging, Inc. 

NANOCIS ® p 29 

Kit for the preparation of technetium ( 99mTc) colloidal rhenium sulphide injection 

(nanocolloid). 

NEUROLITE ® p 30 

Kit for the preparation of technetium ( 99mTc) Bicisate for Injection. Distributed on behalf of 

Lantheus Medical Imaging, Inc. 

OSTEOCIS ® p 30 

Kit for the preparation of technetium ( 99mTc) oxidronate injection. 

PENTACIS ® p 31 

Kit for the preparation of technetium ( 99mTc) pentetate injection. 



PHYTACIS ® p 31 

Kit for the preparation of technetium ( 99mTc) phytate injection. 

PULMOCIS ® p 32 

Kit for the preparation of technetium ( 99mTc) human albumin macroaggregates injection. 

RENOCIS ® p 32 

Kit for the preparation of technetium ( 99mTc) succimer injection. 

SCINTIMUN ® 1 mg p 33 

Kit for labelling of monoclonal antibody (Mab) 

BW 250/183 with technetium ( 99mTc) for 

intravenous injection. 

STAMICIS ® p 34 

Kit for the preparation of technetium ( 99mTc) Sestamibi. 

TECEOS ® p 36 

Kit for the preparation of technetium ( 99mTc) 3,3-diphosphono-1,2 propanedicarboxylic 

acid (DPD) injection. 

VASCULOCIS ® p 36 

Kit for the preparation of technetium ( 99mTc) human albumin injection. 

Accessories 

ELUMATIC ACCESSORIES 

CONT-ELU p 38 

Lead shielding for elution vial. 

CONT-ELU-SP p 38 

All lead glass shielding for elution vial. 

PROTEC-ELU p 38 

Lead shielding for ELUMATIC III generator 

supplied in parts. 

OTHER 

VENTICIS ® II RADIOAEROSOL 

DELIVERY SYSTEM p 39 

Radioaerosol delivery system for lung 

investigation supplied in box of 5 circuits. 

Medical device, class IIa, in compliance with 

the Medical Devices Directive 93/42/EEC. 

0459. 

VENTIBOX p 39 

Lead shielded box for one VENTICIS ® II 

System. 

CAPSION ® p 40 

CARDIOLITE ® /STAMICIS ® p 41 

Radiochemicals 

upon request 

IODINE-124 p 44 

ZIRCONIUM-89 p 44 

Other possibilities upon request. 

The availability of these products is dependant upon their registration status in each country. Please contact your local IBA Molecular representative for 

more information. Please refer to the Summary of Product Caracteristics available on www.iba-molecular.com for complete product information 



Products by nuclide 


169 Er 

ERMM-1 p 18 

Erbium ( 169 Er) citrate for isotopic radiation 

synovectomy (small size joints). 

18 F 

CISNAF ® p 12 

( 18F) Sodium Fluoride is used with positron 

emission tomography (PET). 

DOPACIS ® p 12 

( 18F) Fluorodopa is a solution used with 

positron emission tomography in neurology 

and oncology. 

FARNA FDG 1700 & 3000 p 13 




FDG-IBA P 13 




FLUCIS ® p 14 




FLUORSCAN 1700 & 3000 p 14 




67 Ga 

GA-67-MM-17 p 18 

Gallium ( 67 Ga) citrate: 

- non-specific tumor imaging and/or localizing 

agent. 

- localization of inflammatory lesions. 

123 I 

I-123-S-1 p 19 

Sodium iodide ( 123I) for labelling of 

radiopharmaceuticals. 

I-123-S-2 p 19 

Sodium iodide ( 123I) for functional and 

morphological study of the thyroid gland. 

125 I 

SERALB-125 p 24 

Iodinated ( 125 I) human serum albumin for 

determination of plasma and total blood 

volume, and examination of albumin turnover. 


131I CAPSION ® p 16 

Sodium iodide ( 131I) capsules for thyroid 

therapy. 

I-131-S-1 p 20 

Oral sodium iodide ( 131I) for thyroid therapy. 

I-131-S-2 p 20 

Sodium iodide ( 131I) injection for thyroid 

diagnosis and therapy. 

MIBG-131-D p 21 

Iobenguane ( 131I) for calculation of a 

therapeutic iobenguane ( 131I) dose from a 

prior tracer-dose. 

MIBG-131-T p 21 

Radiation therapy of tumour-tissue that is 

capable of retaining metaiodobenzylguanidine. 

NORCHOL-131 p 22 

6-iodomethylnorcholesterol ( 131I) for 

investigation of adrenocortical diseases. 

186 Re 

RE-186-MM-1 p 23 

Rhenium ( 186 Re) sulphide for isotopic radiation 

synovectomy (medium size joints). 

153 Sm 

QUADRAMET ® p 22 

Samarium ( 153 Sm)-EDTMP for the relief of 

bone pain in patients with multiple painful 

osteoblastic skeletal metastases which take 

up technetium ( 99m Tc)-labelled 

bisphosphonates on bone scan. 

99mTc ANGIOCIS ® p 28 

Kit for the preparation of stannous 

pyrophosphate used for in vivo labelling of 

Red Blood Cells with technetium ( 99mTc). CARDIOLITE ® p 28 

Kit for the preparation of Technetium ( 99mTc) Sestamibi. Distributed on behalf of Lantheus 

Medical Imaging, Inc. 

ELUMATIC ® III p 17 

Sterile technetium ( 99mTc) generator. 

NANOCIS ® p 29 

Kit for the preparation of technetium ( 99mTc) colloidal rhenium sulphide injection 

(nanocolloid). 

NEUROLITE ® p 30 

Kit for the preparation of Technetium ( 99mTc) Bicisate for injection. Distributed on behalf of 

Lantheus Medical Imaging, Inc. 



OSTEOCIS ® p 30 

Kit for the preparation of technetium ( 99mTc) oxidronate injection. 

PENTACIS ® p 31 

Kit for the preparation of technetium ( 99mTc) pentetate injection. 

PHYTACIS ® p 31 

Kit for the preparation of technetium ( 99mTc) phytate injection. 

PULMOCIS ® p 32 

Kit for the preparation of technetium ( 99mTc) human albumin macroaggregates injection. 

RENOCIS ® p 32 

Kit for the preparation of technetium ( 99mTc) succimer injection. 

SCINTIMUN ® 1 mg p 33 

Kit for labelling of monoclonal antibody (MAb) 

BW 250/183 with technetium ( 99mTc) for 

intravenous injection. 

STAMICIS ® p 34 

Kit for the preparation of Technetium ( 99mTc) Sestamibi. 

TECEOS ® p 36 

Kit for the preparation of technetium ( 99mTc) 3,3-diphosphono-1,2 propanedicarboxylic 

acid (DPD) injection. 

VASCULOCIS ® p 36 

Kit for the preparation of technetium ( 99mTc) human albumin injection. 

201 Tl 

TL-201-S-1 p 24 

Thallium ( 201 Tl) chloride for myocardial 

scintigraphy. 

90 Y 

YMM-1 p 25 

Yttrium ( 90Y) citrate colloidal suspension for 

isotopic radiation synovectomy (big size 

joints). 

YTRACIS ® p 25 

Yttrium ( 90Y) chloride radiopharmaceutical 

precursor solution for the radiolabelling of 

carrier molecules. 


124I p 44 

Upon request. 

89Zr p 44 

Upon request. 

The availability of these products is dependant upon their registration status in each country. Please contact your local IBA Molecular representative for 

more information. Please refer to the Summary of Product Caracteristics available on www.iba-molecular.com for complete product information

Product 

specifications 

PET 

Radiopharmaceuticals................................ 11 

SPECT & Therapy 

Radiopharmaceuticals................................ 15 

Cold kits .......................................................... 27 

Accessories .................................................... 37 

Radiochemicals 43 

Packaging 45 

Services 49 



10 | IBA |

PET 




CISNAF ® 

Fluorine-18 T1/2 = 109.77min Fludeoxyglucose ( 18 F) solution for injection 

Availability 

Ordering deadline 

Radioactive concentrations 

Calibration 

Available quantities 

Expiry 

Volume per vial 

Radiochemical purity 

pH and composition 

Storage 

Indication 

DOPACIS ® 

Fluorine-18 T1/2 = 109.77min Fludeoxyglucose ( 18 F) SOLUTION FOR INJECTION 

Availability 



Calibration 


Expiry 




Storage 

Indication 


Depending upon regions 

Please, contact your local IBA representative 



100 MBq/mL at the date and time of calibration 

6 to 10 hours from the time of production 

50 to 1500 MBq per vial at calibration time 

14 hours from the date of production 

0.5 to 15 mL 

≥ 98,5% 

5.0-8.5 ; Sodium floride ( 18 F), sodium chloride and water for injections 

Store in the original packaging 

Medicinal product for diagnostic use only. Indicated for use with 

positron emission tomography (PET) in bone imaging. 

Please, refer to the SPC. 





90 MBq/mL at the date and time of calibration 

2 to 3 hours from the time of production 

90 to 900 MBq per vial at calibration time 

8 hours from the date of production 

1 to 10 mL 

≥ 95% 

4.0-5.5 ; Fluorodopa ( 18F), acetic acid, sodium acetate, ascorbic acid 

and water for injections 

Store in the original lead shielding. After first withdrawal, store in 

refrigerator (2°C to 8°C). 

Medicinal product for diagnostic use only. Indicated for use with 

positron emission tomography in neurology and oncology. 

Please, refer to the SPC. 

IMPORTANT: Read package before using the kit. 

Availability of the products, in the different countries, according to the registration status .

FARNA FDG 1700 & 3000 

Fluorine-18 T1/2 = 109.77 min Fludeoxyglucose ( 18 F) SOLUTION FOR INJECTION 

Availability 



Calibration 


Expiry 



Storage 

Indication 

FDG-IBA 


Availability 


Radioactive concentration 

Calibration 


Expiry 



Storage 

Indication 

From Monday to Friday 

Variable, depending on production sites 

1700 MBq/mL at calibration (FARNA FDG 1700) 

3000 MBq/mL at calibration (FARNA FDG 3000) 

End of synthesis 

From 1.0 to 10.0 mL per vial 

8 hours from the end of synthesis 

≥ 95% 

4.5-8.5 ; Fludeoxyglucose ( 18F); sodium chloride, sodium dihydrogen 

phosphate dihydrate and water for injections 

Do not store above 25°C. Store in the original packaging 

Medicinal product for diagnostic use only. Fludeoxyglucose ( 18F) is 

indicated for use with positron emission tomography 

From Monday to Friday (Saturday in some instances) 


185 MBq/mL at time and date of calibration 

5h, 5h30, 6h or 7h from production 


12 hours from the time of production 

≥ 95% 

4.5 - 8.5 ; Fludeoxyglucose ( 18F), sodium chloride and water for 

injections 

Store in the original package. After first use, store in a refrigerator 

(2 - 8°C) 


indicated for use with Positron Emission Tomography 



FLUCIS ® 


Availability 



Calibration 


Expiry 




Storage 

Indication 

FLUORSCAN 1700 & 3000 


Availability 



Calibration 


Expiry 



Storage 

Indication 



The day before the day of expedition (before 2.00 pm) 

250 MBq/mL at the date and time of calibration 

2 to 4 hours from the time of production 

200 to 2500 MBq per multidose vial at calibration time 

10 hours from the time of production 

0.8 to 10 mL 

≥ 97% 

4.5 - 8.5 ; Fludeoxyglucose ( 18F), sodium chloride and water for 

injections 



indicated for use with Positron Emission Tomography 



1700 MBq/mL at time and date of calibration (FLUORSCAN 1700) 

3000 MBq/mL at time and date of calibration (FLUORSCAN 3000) 

End of synthesis 


8 hours from the end of synthesis 

≥ 95% 

4.5-8.5 ; Fludeoxyglucose ( 18F); sodium chloride, sodium dihydrogen 

phosphate dihydrate and water for injections 



indicated for use with positron emission tomography

SPECT 

& Therapy 




CAPSION ® 

Iodine-131 T1/2 = 8.02 d SODIUM IODIDE ( 131 I) CAPSULE FOR THERAPY 

Availability 



Calibration 

Expiry 

Specific activity at calibration 


Radionuclidic purity 

Storage 

Indication 


Every working day 

The shipment day, before 11 a.m. 

From 50 MBq to 3700 MBq per capsule at calibration 

(100 mCi maxi per capsule) 

On request 1 - 4 days 

21 days after the manufacturing date 

� 185 GBq/mg of iodine at calibration 

Iodide : � 98% 

131 I � 99.9%; 130 I + 133 I + 135 I � 0.1% 

Not above 25°C, in its original packaging. 

• Treatment of Graves’ disease, toxic multinodular goitre or 

autonomous nodules 

• Treatment of papillary and follicular thyroid carcinoma including 

metastatic disease


Technetium 99m Tc generator 

ELUMATIC ® III is an automatic and highly protected generator which produces a sterile and pyrogen free 99mTc solution, 

in the form of sodium pertechnetate (T = 6.02 h). 

This solution is eluted from an alumina chromatographic column on which fission 99Mo is fixed (T = 66 h). 

The ELUMATIC ® III GENERATOR has an activity expressed in 99mTc at the date indicated on the 

label. 

Elution solution : aqueous sterile and pyrogen free 0.9 % sodium chloride and 0.005% sodium nitrate solution. 

Availability and Calibration 


Expiry 

Elution volume 



pH 

Storage 

Precalibred quantities 

Indications 

on Monday calibrated Saturday 12 a.m. 

on Tuesday calibrated Saturday or Wednesday 

(following week) 12 a.m. 

on Wednesday calibrated Wednesday (following week) 12 a.m. 

on Thursday calibrated Wednesday 12 a.m. 

on Friday calibrated Wednesday or Saturday 

(following week) 12 a.m. 

3 days before the shipment day, before 11 a.m. 


5, 10 or 15 ml 

� 95 % 

99 Mo � 0.1 %, 131 I � 5.10 -3 %, 103 Ru � 5.10 -3 %, 89 Sr � 6.10 -5 %, 

90 Sr � 6.10 -6 %, ��1.10 -7 %, other � �0.01 % at the date indicated 

on the label 

4.0-8.0 

At room temperature (15 to 25°C) 

2 - 4 - 6 - 8 - 10 - 12 - 16 - 20 GBq 

1.Reagent for labelling various kits to be used with 99mTc 2.Administered intravenously the eluate might be used in : 

• Thyroid scintigraphy 

• Salivary gland scintigraphy 

• Localization of ectopic gastric mucosa 

• Cerebral scintigraphy 

3.In conjunction with a reducing agent for labelling red blood cells 

for : 

• Cardiac and vascular scintigraphy 

• Diagnosis and localisation of occult gastrointestinal bleeding 

4.Administered by instillation into the eye for : 

• Lacrymal duct scintigraphy 



ERMM-1 

Erbium-169 T1/2 = 9.4 d ERBIUM ( 169 Er) CITRATE SUSPENSION FOR INJECTION 

Availability 



Calibration 


Expiry 

Specific activity 


Storage 

Indication 

GA-67-MM-1 


Tuesday 

Friday before 11 a.m. 

111 MBq/ml (3 mCi/ml) 

Saturday 12 a.m. 

From 37 to 1110 MBq 

18 days from the manufacting date 

37 to 1110 MBq/mg (1 to 30 mCi/mg) 

5.5 - 7.5 in sodium chloride solution 

At room temperature (15 to 25°C) 

Treatment of rheumatoid mono or oligo-arthritis involving one or few of 

the small joints of the hands and feet following failure of intra-articular 

corticosteroid therapy or when the latter is contra-indicated 

Gallium-67 T1/2 = 3.26 d GALLIUM ( 67 Ga) CITRATE SOLUTION FOR INJECTION 

Availability 



Calibration 


Expiry 





Storage 

Indication 

Monday, Friday 

2 days before the shipment day, before 10 a.m. 


Monday (next week) Friday (next week) 12 a.m. 



Carrier free 

� 95 % 

� 99 %; 66 Ga � 0.2 % 

5 - 8 in sodium citrate solution 

Not above 25°C 

2 - 8°C after the first withdrawals 

• Non-specific tumor imaging and/or localising agent 

• Localisation of inflammatory lesions

I-123-S-1 

Iodine-123 T1/2 = 13.2 h SODIUM IODIDE ( 123 I) SOLUTION FOR LABELLING 

Availability 



Calibration 


Expiry 





Storage 

Indication 

I-123-S-2 

Iodine-123 T1/2 = 13.2 h SODIUM IODIDE ( 123 I) SOLUTION FOR INJECTION 

Availability 



Calibration 


Expiry 





Storage 

Indication 

Every working day except Thursday, Friday and the day before a 

day off 

One day before (before 11 a.m.) 

3700 MBq/ml (100 mCi/ml) 

Following day at 5 p.m. 

92.5 - 148 - 185 - 259 - 296 MBq 

2.5 - 4 - 5 - 7 - 8 mCi 


Carrier free 

� 95 % 

� 99.7 % 

� 7 in sodium hydroxide 0.02 N 


Labelling of radiopharmaceuticals 

Every working day except Friday and the day before 

a french banking holiday 

One day before (before 11 a.m.) 

18.5 MBq/ml (0.5 mCi/ml) 

Following day at 5 p.m. 

18.5 to 185 MBq (0.5 to 5 mCi) 


Carrier free 

� 95 % 

� 99.7 % 

6.5 - 7.5 phosphate-thiosulfate buffer 


Functional and morphological study of the thyroid gland 



I-131-S-1 

Iodine-131 T1/2 = 8.02 d SODIUM IODIDE ( 131 I) ORAL SOLUTION 

Availability 



Calibration 


Expiry 

Specific activity at calibration 


Radionuclidic purity at calibration 


Storage 

Indication 

I-131-S-2 


Tuesday 

Friday, before 11 a.m. 

1110 MBq/ml (30 mCi/ml) at calibration date 

Wednesday (following week) 12 a.m. 

From 1110 to 11 100 MBq 


� 185 GBq/mg iodine 

Iodide : � 95 % 

� 99.9 %; 133 I + 135 I + other alpha impurities � 0.1 % 

7 - 10 in sterile solution with carbonate-thiosulfate buffer 


Diagnostic 

• Estimation of thyroid uptake and effective half life 

• Identification of thyroid remnant and metastases (after ablation) 

Therapy 

• Treatment of Graves’ disease, toxic multinodular goitre or 



metastatic disease 

Iodine-131 T1/2 = 8.02 d SODIUM IODIDE ( 131 I) SOLUTION FOR INJECTION 

Availability 



Calibration 


Expiry 





Storage 

Indication 

Thursday 

2 days before the shipment day, before 10 a.m. 


Friday (following week) 12 a.m. 



� 185 GBq/mg at calibration 

Iodide : � 95 % 

� 99.9 %; 133 I + 135 I + other alpha impurities � 0.1 % 

6 - 8 in phosphate-thiosulfate buffer 


Diagnostic 

• Estimation of thyroid uptake and effective half life 

• Management of thyroid carcinoma : identification of thyroid remnant 

and metastases (after ablation) 

Therapy 

• Treatment of Graves disease, toxic multinodular goitre or 



metastatic disease

MIBG-131-D 

Iodine-131 T1/2 = 8.02 d IOBENGUANE ( 131 I) SOLUTION FOR INJECTION (DIAGNOSIS) 

Availability 



Calibration 


Expiry 





Storage 

Indication 

MIBG-131-T 

Monday 

Wednesday 11 a.m., the week before the shipment day 

9.25 MBq/ml (0.25 mCi/ml) 

Tuesday (following week) 12 a.m. 

Monodose of 46.25 MBq (1.25 mCi) 


46.25 MBq/vial (1.25 mCi/mg MIBG) = 54.5 GBq/g iobenguane at 

calibration 

� 94 % 

131I � 99.9 % ; 133 I + 135 I � 0.1 % 

4 - 6 in saline acetate buffer 

At - 18°C 

Calculation of a therapeutic iobenguane ( 131I) dose from a prior 

tracer-dose (used for dosimetry in pheochromocytomas, 

neuroblastomas, carcinoids and medullary carcinomas of the thyroid 

gland) 

Iodine-131 T1/2 = 8.02 d IOBENGUANE ( 131 I) SOLUTION FOR INJECTION (THERAPY) 

Availability 



Calibration 


Maximum activity / vial 

Expiry 





Storage 

Indication 

Two first Tuesday of each month 

Thursday 11 a.m. 

370 MBq/ml (10 mCi/ml) 

Thursday 12 a.m. 

1850 - 3700 and 5550 MBq (50 - 100 and 150 mCi) 

5550 MBq (150 mCi) 


� 400 GBq/g iobenguane at calibration 

� 92 % 

131 I � 99.9 % 

3.5 - 5.5 in saline acetate buffer 

At - 18°C 

Radiation therapy of tumour-tissue that is capable of retaining 

metaiodobenzylguanidine: pheochromocytomas neuroblastomas, 

carcinoid and medullary carcinomas of the thyroid gland 



NORCHOL-131 

Iodine-131 T1/2 = 8.02 d ( 131 I) IODOMETHYLNORCHOLESTEROL SOLUTION FOR INJECTION 

Availability 



Calibration 


Expiry 




pH 

Storage 

Indications 

QUADRAMET ® 


Thursday 

Friday, before 11 a.m. 

7.5 - 15 MBq/ml (0.2 - 0.4 mCi/ml) at calibration 

Wednesday 12 a.m. 

From 37 to 74 MBq per vial at calibration 


11 - 33 MBq/mg (0.3 - 0.9 mCi/mg) 

� 85 % 

� 99.9 % 

3.5 to 8.5 

At - 18°C 

• Diagnostic evaluation of the functional state of adrenal cortical 

tissue 

• Differentiation between metastatic disease to the adrenals (“cold 

area”) and non-malignant adrenal enlargement in cancer patients 

• Detection of remnants of functioning tissue in hypercortisonism 

after adrenalectomy, or of ectopic endocrine tissue 

• Detection and follow-up of euadrenal tumours 

Samarium-153 T1/2 = 46.3 h SAMARIUM ( 153 Sm) LEXIDRONAM PENTASODIUM SOLUTION FOR INJECTION (THERAPY) 

Composition 

Available activities 

Posology and method 

of administration 

Availability and Calibration 


Expiry 

Storage 

Therapeutic indications 

( 153Sm-EDTMP) : 1.3 GBq/ml (at calibration date) 

(Corresponding to 20 to 46 mg/ml of samarium) 

Total EDTMP (as EDTMP.H20) : 33 mg/ml 

Calcium-EDTMP sodium salt (as Ca) 

Total sodium (as Na) 

Water for injections 

2 to 4 GBq per vial at calibration date 

• 37 MBq per kg body weight 

• Slow intravenous route through an established intravenous line over 

a period of one minute 

• Should not be diluted before use 

On Monday calibrated Thursday 12 a.m. 

On Friday calibrated Monday 12 a.m. 

1 day before the shipment day, before 11 a.m. 

4 days after the manufacturing date (1 day after the calibration date) 

• Delivered frozen in dry ice, should be stored frozen at -10°C to 

-20°C in its original packaging 

• Use within 6 hours of thawing 

• After thawing, do not freeze again 

Relief of bone pain in patients with multiple painful osteoblastic 

skeletal metastases which take up technetium ( 99mTc)-labelled biphosphonates on bone scan

RE-186-MM-1 

Rhenium-186 T1/2 = 3.77 d RHENIUM ( 186 Re) SULPHIDE SUSPENSION FOR INJECTION 

Availability 



Calibration 


Expiry 





Storage 

Indication 

Tuesday 


148 to 370 MBq/ml (4 to 10 mCi/ml) 


From 37 to 3700 MBq 

10 days after the manufacturing date 

2000 to 7400 MBq/mg (54 to 200 mCi/mg) 

� 95 % 

186 Re � 99 %; 184 Re + 188 Re � 1% 

3.5 - 5.5, colloidal suspension stabilised with gelatine 


• Treatment of rheumatoid mono or oligo arthritis involving mediumsized 

joints (shoulders, elbows, wrists, ankles, hips) and particularly 

rheumatoid polyarthritis 

• Treatment of haemophilic or chronic arthropathy associated with 

articular chondrocalcinosis. 



SERALB-125 

Iodine-125 T1/2 = 59.9 d IODINATED ( 125 I) HUMAN ALBUMIN SOLUTION FOR INJECTION 

Availability 



Calibration 


Expiry 





Storage 

Indication 

TL-201-S-1 

Thallium-201 T1/2 = 3.05 d THALLIUM ( 201 Tl) CHLORIDE SOLUTION FOR INJECTION 

Availability and calibration 




Expiry 





Storage 

Indication 


Thursday (twice a month) 

Monday, before 11 a.m. 

185 kBq/ml (5 µCi/ml) 

Saturday (2 weeks after) 12 a.m. 

Per 4 vials of 320 kBq (8.6 µCi) 


167 to 204 kBq/ml 

� 80 % 

� 99 % 

5 - 9 

At 2 to 8°C in its original packaging 

• Determination of plasma volume and total blood volume 

• Examination of albumin turnover. 

On Monday calibrated Friday noon 

On Tuesday calibrated Sunday noon 

On Wednesday calibrated Tuesday noon 

On Thursday calibrated Wednesday noon 

On Friday calibrated Thursday noon 

1 day before the shipment day, before 11 a.m. 

37 MBq/ml (1mCi/ml) 



� 3.7 MBq/µg (0.1 mCi/µg) 

� 95 % 

� 97 % 

Release Expiry 

200 Tl < 0.25 % < 0.01 % 

202 Tl < 0.50 % < 2.00 % 

203 Pb < 0.10 % < 0.05 % 

4 - 7 in sterile isotonic solution 


2 - 8°C after the first withdrawal 

• Myocardial scintigraphy in the evaluation of coronary perfusion 

and cellular viability. 

• Scintigraphy of the muscles. 

• Parathyroid scintigraphy. 

• Thallium avid tumour visualisation in different organs, 

especially for the brain tumours and thyroid tumours 

and metastases.

YMM-1 

Yttrium-90 T1/2 = 2.67 d YTTRIUM ( 90 Y) CITRATE SUSPENSION FOR INJECTION 

Availability 



Calibration 


Expiry 


Non filtrable fraction 

of Yttrium-90 citrate colloidal 

suspension 


Storage 

Indication 

YTRACIS ® 

Availability 



Calibration 


Expiry 



Acidity 

Storage 

Indication 

Tuesday 


37 to 370 MBq/ml (1 to 10 mCi/ml) 




59 to 300 MBq/mg 

� 85% at release - � 80% at expiry 

5.5 - 7.5 in sodium chloride solution 


Therapeutic irradiation of synovial hypertrophy of knee joints mainly 

for mono- or oligo-articular arthritis of chronic inflammatory 

rheumatism particularly rheumatoid polyarthritis 

Yttrium-90 T1/2 = 2.67 d YTTRIUM ( 90 Y) CHLORIDE RADIOPHARMACEUTICAL PRECURSOR SOLUTION 

Tuesday 

Thursday before 2 p.m. 

1.85 GBq/ml 

Friday 12 a.m. CET 

1.85 GBq 


Carrier free 

� 97 % 

0.035M-0.045M 

Store in its original packaging 

To be used only for the radiolabelling of carrier molecules which have 

been specifically developed and authorized for radiolabelling with this 

radionuclide. 




SPECT 

Cold kits 

(Kits for radiopharmaceutical preparation with Technetium 99m Tc) 



ANGIOCIS ® 

Kit for the preparation of stannous pyrophosphate used for in vivo labelling of 

red blood cells with technetium ( 99m Tc) 

Each vial contains : 

Sodium pyrophosphate decahydrate 20.12 mg 

Stannous chloride dihydrate 

Volume of 0.9% sodium chloride sterile 

solution to use for reconstitution 3 ml 

Storage 12 months at 2 to 8°C 

Stability of reconstituted product 6 h at 2 to 8°C 

Indications /Posology • Angiocardioscintigraphy 

• Organ perfusion and vascular abnormality imaging 

• Diagnosis and localisation of occult gastro-intestinal bleeding 

Activity injected for blood pool scintigraphy (740 - 925 MBq) 

Time between injection of Angiocis and 30 minutes before administration of pertechnetate 99m Tc 

pertechnetate 99m Tc 

Time between injection and examination Immediatly after injection of the tracer (pertechnetate 99m Tc) 

Availability From stock 

Number of radiolabelled preparations per kit 5 

CARDIOLITE ® 

Kit for the preparation of technetium ( 99m Tc) sestamibi injection 

Tetrakis (2-methoxy isobutyl isonitrile) 1.0 mg 

copper (I) tetrafluoroborate (Cu (MIBI) 4 BF 4 ): 


L-cysteine hydrochloride monohydrate 

Sodium Citrate Dihydrate 

Mannitol 

Volume of 99m Tc pertechnetate 1 to 3 ml 

Radiochemical purity > 94% 

Indications /Posology Diagnosis of reduced coronography perfusion and myocardial 

infarction: 185-740 MBq 

Assessment of global ventricular function: 

600-800 MBq injected as a bolus 

Scinti-mammography: 


Parathyroid imaging 


Time between injection and examination Cardiac imaging 

1-2 hours after rest injection and stress injection. Imaging for up 

to 6 hours post injection is possible 

Breast imaging 

Planar images should be acquired 5 to 10 min after injection for 

10 min each 


In order to visualize the parathyroid, either pertechnetate ( 99m Tc) or 

iodine ( 123 I) can be given first, followed by technetium ( 99m Tc) 

sestamibi, or technetium ( 99m Tc) sestamibi can be given first, 

followed by pertechnetate ( 99m Tc). 

When iodine ( 123 I) is used, 10 to 20 MBq of oral iodine ( 123 I) are 


IMPORTANT : Read package leaflet before using the kit 

“Availability of the products, in the different countries, according to the registration status”

CARDIOLITE ® 

(continued) 

administered. Four hours after the administration of 123 I, neck and 

thorax images are obtained. After iodine ( 123 I) image acquisition, 

185 to 370 MBq of technetium ( 99m Tc) sestamibi are injected and 

images are acquired 10 minutes post injection in double 

acquisition with 2 peaks of gamma energy (140 keV for 

technetium ( 99m Tc) and 159 keV for iodine ( 123 I)). 

When pertechnetate ( 99m Tc) is used to visualize the parathyroid, 

40-150 MBq of sodium pertechnetate ( 99m Tc) are injected and 

neck and thorax images are acquired 30 minutes later. Then 185- 

370 MBq of technetium ( 99m Tc) sestamibi are injected and a 

second acquisition of images is acquired 10 minutes later. 

After a wash-out period of 1 to 2 hours, neck and thorax imaging 

is again performed. 

Storage 24 months at 15 - 25°C, protected from light 

Stability of labelled product 10 h at 15 - 25°C, protected from light 

Activity per vial Maximum 11.1 GBq (300 mCi) 



NANOCIS ® 

Kit for the preparation of technetium ( 99m Tc) colloidal rhenium sulphide 

injection (Nanocolloid) 

Vial A 

Rhenium sulfide (as Re element 0.15 mg) 0.24 mg 

Gelatin 

Ascorbic acid 

Water for injections 

Concentrated hydrochloric acid 

Vial B 

Sodium pyrophosphate decahydrate 


Sodium hydroxide 

Particle size 31.6 nm < 70% < 178 nm 

Volume of pertechnetate 99m Tc to add vial A 1 to 2 ml 

Radiochemical purity � 95% 

Aspect of reconstituted product Dark brown colloidal solution 

Storage 6 months at 2 - 8°C 

Stability of labelled product 4 h at 2 - 8°C 

Activity per vial 370 to 5550 MBq (10 to 150 mCi) 

Indications /Posology 1) Imaging and detection of sentinel lymphnode : 

3.7 to 200 MBq: activity and volume injected depending on the 

indication. Please refer to the SPC 

2) Lymphatic flow scintigraphy : 

20 to 200 MBq (0.5 to 5 mCi) in 0.2 to 0.3 ml / site 

Vol max/injection site: 0.5 ml 

3) Gastro Oesophageal Reflux : 

3.5 to 12 MBq (0.1 to 0.3 mCi) 




“Availability of the products, in the different countries, according to the registration status” 



NEUROLITE ® 

Kit for the preparation of technetium ( 99m Tc) bicisate injection 

Vial A 

Bicisate dihydrochloride 900 µg 

Stannous Chloride dihydrate 

Disodium edetate, Mannitol, Hydrochloric acid 

Nitrogen (headspace) 

Vial B 

Disodium phosphate heptahydrate 

(Na 2 HPO4 • 7H 2 O) 

Sodium dihydrogen phosphate monohydrate 

(NaH 2 PO4 • 1H 2 O) 

Water for injection 

Volume of 99m Tc pertechnetate to add in vial B 2 ml 


Indications /Posology Tc-99m Bicisate scintigraphy is indicated in the evaluation of 

regional cerebral perfusion abnormalities in adult patients with 

central nervous system disorders 

The recommended dose for intravenous injection is 740 MBq 

(20 mCi) in the average patient (70 kg) 

Time between injection and examination Within 6h 

Storage 18 months 

Activity per vial 3700 MBq (100 mCi) 

Stability of labelled product 8h at < 25°C 



OSTEOCIS ® 

Kit for the preparation of technetium ( 99m Tc) Oxidronate injection 


Sodium oxidronate (HMDP) 3.0 mg 


Ascorbic acid 

Sodium chloride 

Under nitrogen atmosphere 

Volume of pertechnetate 99m Tc 

to use for reconstitution 2 to 10 ml 

Radiochemical purity � 95 % 


Activity per vial 0.74 to 11.1 GBq 

Indications / Posology Bone scintigraphy 

500 MBq 

300 to 700 MBq / 50 or 70kg adult 

After reconstitution with sodium pertechnetate ( 99m Tc) solution, the 

agent may be used for bone scintigraphy, where it delineates 

areas of altered osteogenesis 

Stability of labelled product 8h at 2 - 8ºC 

Time between injection and examination not earlier than 2h after injection 






PENTACIS ® 

Kit for the preparation of technetium ( 99m Tc) pentetate injection 


Calcium trisodium pentetate (DTPA Ca Na 3 ) 9.10 mg 



Under a nitrogen atmosphere 


to use for reconstitution 5 ml 



Activity per vial 3.7 to 2000 MBq 

Indications / Posology 1) Intravenous use : 

- Renal glomerular filtration 1.8 to 3.7 MBq (plasma) 

- Renal glomerular filtration 37 to 370 MBq (scanning) 

- Brain scanning 185 to 740 MBq 

2) Oral use : Study of gastro-oesophageal reflux and gastric 

emptying : 10 to 20 MBq 

Stability of labelled product 4h at 2 - 8°C with a maximum of 5 withdrawals per vial 

Time between administration and examination Optimal static renal imaging : 1 hour 

Renal and brain sequential 

scanning : immediately 

Brain static images : 1 hour to several hours 

Dynamic recording : first minutes up to 120 minutes for 

gastroduodenal transit. 



PHYTACIS ® 

Kit for the preparation of technetium ( 99m Tc) phytate injection 


Sodium phytate 20 mg 


Sodium hydroxide 



to use for reconstitution 10 ml max. 




Activity per vial 9250 MBq max. 

Indications /Posology Hepatic scintigraphy : 37 to 100 MBq 

Time between injection and examination 10 to 60 min 







PULMOCIS ® 

Kit for the preparation of technetium ( 99m Tc) human albumin macroaggregates 

injection 


Human Albumin Macroaggregates (MAA) 2.0 mg 



Non denaturated human albumin 


Particles number per vial 2 to 4 million 

Particle size Number of MAA � 150 �m - 0 

Number of MAA � 100 �m - � 10 


to use for reconstitution 2.5 - 10 ml 


Colour Homogeneous suspension 

Storage 12 months at 2 - 8 °C 


Indications Pulmonary perfusion scintigraphy 

Venoscintigraphy 

Posology 37 to 185 MBq 


Time between injection and examination Immediately 

Availability from stock 


RENOCIS ® 

Kit for the preparation of technetium ( 99m Tc) succimer injection 


Dimercaptosuccinic acid (DMSA) 1.0 mg 


Inositol 

Ascorbic acid 

Sodium hydroxide (pH adjustment) 



to use for reconstitution 1 to 6 ml 




Activity per vial Maximum 3.7 GBq 

Indications /Posology Static planar or tomographic renal imaging : 

- Morphological studies of renal cortex 

- Individual kidney function 

- Location of ectopic kidney 

30 to 120 MBq 

Time between injection and examination Image acquisitions : 1 to 3 h 

Where there is renal impairment or obstruction, delayed views 

may be needed (6 to 24 hours respectively) 






SCINTIMUN ® 1mg 

Kit for radiopharmaceutical preparation for the labelling of anti-granulocyte 

monoclonal antibody (MAb) BW 250/183 with technetium ( 99m Tc) 

Each vial 1 contains 5.02 mg dry substance : 

Besilesomab 1 mg 

Disodium hydrogen phosphate, anhydrous 

Sodium dihydrogen phosphate, anhydrous 


Sorbitol E420 

Each vial 2 contains 3 mg dry substance : 

1,1,3,3-propane tetraphosphonic acid, 

tetrasodium salt, dihydrate (PTP) 2.7 mg 

Tin (II) chloride dihydrate 

Sodium hydroxyde 1N (pH adjustment) 

Hydrochloric acid 1N (pH adjustment) 





Storage 2 years at 2 - 8°C, protected from light 

Stability of labelled product 3 h not above 25°C 

Protected from light 

Activity per vial 400 to 1800 MBq 

Indications /Posology In conjunction with other appropriate imaging modalities 

determination of the location of inflammation/infection peripheral 

bone in adults with suspected osteomyelitis (400-800 MBq). 

Should not be used for the diagnosis of diabetic foot infection 

Time between injection and examination 3 to 6h and late image 24h 


Number of labelling sets per pack 1 or 2 







STAMICIS ® 

Kit for the preparation of technetium ( 99m Tc) sestamibi injection 

Tetrakis (2-methoxy isobutyl isonitrile) 1.0 mg 

copper (I) tetrafluoroborate (Cu (MIBI) 4 BF 4 ) 


L-cysteine hydrochloride monohydrate 

Sodium Citrate Dihydrate 

Mannitol 

Volume of 99m Tc pertechnetate 1 to 3 ml 


Indications /Posology Adults 

The suggested activity range for intravenous use to a patient of 

average weight (70 kg) is: 

Myocardial perfusion scintigraphy: 400-900 MBq 

Assessment of global ventricular function: 600-800 MBq injected 

as a bolus. 

For diagnosis of ischaemic heart disease two injections (stress 

and rest) are required in order to differentiate transiently from 

persistently reduced myocardial uptake. 

The recommended activity range for diagnosis of ischaemic heart 

disease according to the European procedural guideline is: 

- Two-day protocol: 600–900 MBq/study 

- One-day protocol: 400–500 MBq 

for the first injection, three times more for the second injection. 

Not more than a total of 2000 MBq should be administered for a 

one-day protocol and 1800 MBq for a two-day-protocol. For a one 

day protocol, the two injections (stress and rest) should be done 

at least two hours apart but may be performed in either order. 

After the stress injection, exercise should be encouraged for an 

additional one minute (if possible). 

For diagnosis of myocardial infarction one injection at rest may be 

sufficient. 

The injection of activities greater than local DRLs (Diagnostic 

Reference Levels) should be justified. 

Scinti-mammography for the detection of suspected breast 

cancer: 750-1000 MBq injected as a bolus in the arm opposite to 

the lesion. 

Localisation of hyperfunctioning parathyroid tissue: 200- 

1000 MBq injected as a bolus (the activity used should in every 

case be as low as reasonably practical). The typical activity is 

740 MBq. 

Children and adolescents 

For pediatric use, please refer to the full SPC. 

Time between injection and examination Myocardial perfusion scintigraphy 

If possible, patients should fast for at least four hours prior to the 

study. It is recommended that patients eat a light fatty meal or 

drink a glass or two of milk after each injection, prior to imaging. 

This will promote rapid hepatobiliary clearance of technetium 

( 99m Tc) sestamibi resulting in less liver activity in the image. 

Imaging should begin approximately after 60 min after injection to 

allow for hepatobiliary clearance. Longer delay can be required 

for resting images and for stress with vasodilatators alone 

because of the risk of higher subdiaphragmatic 99m Tc activity. 

There is no evidence for significant changes in myocardial tracer 

concentration or redistribution, therefore imaging for up to 6 hours 

post injection is possible. Test may be done in a one day or two 

days protocol. 

Preferably tomographic imaging (SPECT) with or without ECG 




STAMICIS ® 

(continued) 

gating should be performed according to current international 

guidelines. 

Breast imaging 

The product is administered in an arm vein contralateral to the 

breast with the suspected abnormality. If the disease is bilateral, 

the injection is ideally administered in a dorsal vein of the foot. 

Breast imaging is optimally initiated 5 to 10 minutes post injection 

with the patient in the prone position with breast freely pendant. A 

10 minute lateral image of the breast suspected of containing 

cancer should be obtained with the camera face as close to the 

breast as practical. 

The patient should then be repositioned so that the contralateral 

breast is pendant and a lateral image of it should be obtained. An 

anterior supine image may then be obtained with the patient’s 

arms behind her head. 


Acquisition depends on the protocol chosen. The most used 

studies are either the dual-phase and/or the subtraction 

techniques, which can be performed together. 

• Subtraction technique of the activity of the thyroid: 

In order to visualize the parathyroid, either pertechnetate( 99m Tc) or 

iodine ( 123 I) can be given first, followed by technetium ( 99m Tc) 

sestamibi, or technetium ( 99m Tc) sestamibi can be given first, 

followed by pertechnetate ( 99m Tc). 

When iodine ( 123 I) is used, 10 to 20 MBq of oral iodine ( 123 I) are 

administered. Four hours after the administration of 123 I, neck and 

thorax images are obtained. After iodine ( 123 I) image acquisition, 

185 to 370 MBq of technetium ( 99m Tc) sestamibi are injected and 

images are acquired 10 minutes post injection in double 

acquisition with 2 peaks of gamma energy (140 keV for 

technetium ( 99m Tc) and 159 keV for iodine ( 123 I)). 

When pertechnetate ( 99m Tc) is used to visualize the parathyroid, 

40-150 MBq of sodium pertechnetate( 99m Tc) are injected and neck 

and thorax images are acquired 30 minutes later. Then 185- 

370 MBq of technetium ( 99m Tc) sestamibi are injected and a 

second acquisition of images is acquired 10 minutes later. 

• Dual-phase study: 

350-1000 MBq of technetium ( 99m Tc) sestamibi are injected. Early 

(10 min. postinjection) and delayed (1.5-2.5 h postinjection) highcount 

images are obtained. 

In case of kidney failure, exposure to ionising radiation can be 

increased. This must be taken into account when calculating the 

activity to be administered. 

In general, activity selection for patients with a decreased hepatic 

function should be cautious, usually starting at the low end of the 

dosing range. 

Storage 1 year not above 25°C 

Stability of labelled product 10 h at 2 - 8°C 

Activity per vial Maximum: 11 GBq (300 mCi) 







TECEOS ® 

Kit for the preparation of technetium ( 99m Tc) 

3,3-diphosphono-1,2-propanedicarboxylic acid (DPD) injection 


3,3-diphospho - 1,2 -propanedicarboxylic 

acid, tetrasodium salt (DPD) 13.0 mg 

tin (II) - oxide 

N - (4 - aminobenzoyl) - L - glutamic acid, 

monosodium salt 


to use for reconstitution 2 to 10 ml 


Storage 13 months, not above 25°C 


Activity per vial 0.37 to 11.1 GBq 

Indications /Posology Bone scintigraphy 500 MBq 

(300 - 700 MBq) 

Time between injection and examination Late phase static scintigraphy should be performed 

not earlier than 2 hours 



VASCULOCIS ® 




Kit for the preparation of 

technetium ( 99m Tc) human albumin injection 


Human Serum Albumin (HSA) 10 mg 









Indications /Posology 1) Static blood pool imaging : 111 to 185 MBq 

2) Angiography : 370 to 740 MBq 

3) Circulation, blood flow studies : 18.5 to 185 MBq 

4) Ventriculography : 185 to 925 MBq 


Time between injection and examination Shortly or immediately 





SPECT 

Accessories 



ELUMATIC ® III generator accessories 

TC - ELU - 5 - 50 

Kit containing 50 vials of 5 ml vacuum, sterile and pyrogen 

free, for the elution of the ELUMATIC ® III generator. 

TC - ELU - 5 - 150 

Kit containing 150 vials of 5 ml vacuum, sterile and 

pyrogen free, for the elution of the ELUMATIC ® III generator. 

TC - ELU - 10 - 50 

Kit containing 50 vials of 10 ml vacuum, sterile and 


TC - ELU - 10 - 150 

Kit containing 150 vials of 10 ml vacuum, sterile and 


TC - ELU - 15 - 50 



TC - ELU - 15 - 150 




CONT - ELU 

Lead container for the protection of vacuum vials for the 

elution of the ELUMATIC ® III generator (with a flat lead 

glass window). 

CONT - ELU - SP 

Total vision lead glass and lead container for the protection 

of vacuum vials for the elution of the ELUMATIC ® III 

generator. 

PROTEC - ELU 

Additional shielding for storage and elution of the 

ELUMATIC ® III generator (160 kg). 

Depending on national regulations.

Venticis ® II and accessories 

VENTICIS ® II - RADIOAEROSOL DELIVERY SYSTEM 

Venticis ® is an aerosol generator intended for 

- Study of pulmonary ventilation 

- Study of alveolar-capillary permeability 

using radiopharmaceutical products labelled with technetium 99m. Medical device, class IIa, CE marked, in compliance with the Medical Devices Directive 93/42/EEC. 

0459 

1 - Nebulizer 

2 - Air supply tubing 

3 - External 

loader 

4 - Reservoir bag 

5 - Valves 

6 - Mouthpiece 

7 - Filter trap 

8 - Lead shielded box 

Availability : from stock, by 5 units 

99m Tc aérosol inhalé 

Inhaled 99m Tc aerosol 

VENTIBOX - LEAD SHIELDED BOX FOR ONE VENTICIS ® II SYSTEM 

Size closed box 

l. : 220 mm 

w. : 154 mm 

h. : 360 mm 

w. : 16 kg 

99m Tc aérosol exhalé 

Exhaled 99m Tc aerosol 



CAPSION ® accessories 

Tong Transportation system for 131 Iodine capsule 

Lead transportation pot for 131 Iodine capsule Perforator 

Guide 


STAMICIS ® /CARDIOLITE ® accessories 

Tong Boiler 

QC strips Lead protection for Stamicis ® /Cardiolite ® vials 





Iodine-124 

Zirconium-89 



IODINE-124 

(I-124) 

Iodine-124 is a radiochemical 

NOT FOR HUMAN USE 

Definition 

Production 

Characters 

Identification 

Test 




Chemical purity 

Radioactivity 

Zirconium-89 

(Zr-89) 

Zirconium-89 is a radiochemical 

NOT FOR HUMAN USE 

Definition 

Production 

Half-life 

Identification 

Test 





Solution containing iodine-124 in the form of sodium iodide. 

Content: 90% to 110% of the declared iodine-124 radioactivity at the 

date and hour stated on the label. 

Iodine-124 is produced by proton irradiation of tellurium enriched in 

Tellurium-124 (minimum 98%). No carrier iodine is added. 

Appearance: clear, colourless solution. 

Gamma-ray spectrometry: the most prominent gamma photon has an 

energy of 602,7 keV. 

pH: higher than 10 

Sterility: Not tested for. 

Bacterial endotoxins: Not tested for. 

> 740 MBq / ml ( > 20 mCi / ml ) in 1 ml glass vial 

Iodine-124: minimum 99 % of the total radioactivity at calibration date. 

Iodine-123: less than 0.5% at calibration date. 

Iodine-125: less than 0.1% at calibration date. 

[ 124I] iodine : minimum 95% of the total activity. 

Tellurium content: less than 1 µg/ml 

Determine the radioactivity using a calibrated instrument. 

Zirconium-89 in 1 mol/L oxalic acid. 

Zirconium-89 is produced by proton irradiation of natural yttrium 

(Y-89) 

78.4 hours. 

Gamma-ray spectrometry: the most prominent gamma photon has an 

energy of 909 keV 

pH: lower than 4; 

Sterility: not tested for; 

Bacterial endotoxins: not tested for 

Between 740 – 1850 MBq/mL (20 – 50 mCi/mL) at calibration in 

2.0 mL V-bottom screw top glass vials. 

> 99.9% zirconium-89 at calibration 

No carrier added.

Packaging 

PET 

SPECT 



FDG-IBA 

Vial Lead pot 

FLUCIS ® 

Vial 

Drum 


Lead pot 

PET


SPECT 

15 ml penicillin type vial Lead shields (according to nominal activities) 

Metallic box (easy open system) Packaging 


Drum 



Cold Kits 

Five sizes of packaging for cold kits 


SPECT

Services 




DopaSoft 

Dopasoft is a software which allows standardized access to the static 

analysis of brain 18F-DOPA PET studies. 

Dopasoft ensures the normalization of images, placement of volumes of 

interest, calculation of the SOR (Striatum to Occipital Ratio) and comparison 

to a database of healthy subjects. 

Imagem 

Imagem is an educational web plateform on molecular imaging 

Imagem includes : 

- Practical training, written by experts, on major radiopharmaceuticals. 

- An extensive view of PET/CT knowledge written by a team of 18 experts 

led and coordinated by Professor Peter J. Ell. 

- A unique database on Molecular Imaging (scientific articles, news and 

events) updated daily by information specialists. 

Molybdenum supply review 

Molecular Supply Review keep you up to date with the latest Molybdenum 

supply developments in order to provide you with alternative non-technetium 

products during the most severe shortage periods. 

Frequency: 2/3 months 

Molecular imaging review 

Molecular Imaging Review consolidates the key information published in 

the Molecular Imaging world. It includes PET/SPECT scientific articles in 

the major clinical axis (books, abstracts, events, news/press). 

Frequency: Monthly

General 

Information 

Commercial information ............................ 52 

Scientific and technical information .... 53 

Units.................................................................. 55 

Definitions ...................................................... 56 

Nuclides index .............................................. 57 

Radioactive decay table ............................ 59 

Locations and contacts ............................ 63 



Commercial information 

PACKAGING 

Radioactive products are delivered in packaging in 

accordance with procedures complying with the : 

• RECOMMENDATIONS of the International Atomic 

Energy Agency in Vienna (IAEA) (1990 revised edition) 

and with the ensuing regulations, codes and 

agreements. 

• International Air Transport Association (IATA) Regulations. 

• International Rail Transport Regulations (RID). 

• International Maritime Code (OMCI) 

• European Agreement on International Road Transport 

(ADR) 

• French regulations on transport of radioactive materials. 

Determination of the type of packaging is settled by the 

dangerous nature of the transported material : depending 

on its radiotoxicity, radioactivity and its tendency to spread. 

ORDERING INFORMATION 

1. HOW TO ORDER ? 

Orders may be placed by mail, telefax or telephone to your 

local contact (see list on the back of the catalogue). To 

avoid errors and delay, each order should include the 

following information : 

- ship to : CUSTOMER’S NAME + ADDRESS 

- invoice : NAME + ADDRESS (if different) 

- PURCHASE ORDER NUMBER 

- CATALOGUE CODE + NAME OF PRODUCT 

- QUANTITY REQUIRED 

- DELIVERY DATE REQUIRED 

- SPECIAL PACKAGING OR SHIPPING INSTRUCTIONS. 

If a written order is confirmation of an order already 

placed by telephone, this must be clearly indicated. 

Duplicate shipment resulting from improperly confirmed 

formal order may not be returned for credit and both 

invoices are integrally payable. 

Standing orders : 

We welcome standing orders. They can be modified or 

cancelled at any time, with at least one week’s notice. 


For each radioactive nuclide, regulations lay down 

maximum quantity limits of radioactivity defined as : 

• type A packaging : low and medium radioactivity, 

• type B packaging : high radioactivity. 

Packaging used for radiopharmaceutical products is type 

A non-returnable packaging ; it complies with the 

regulatory tests for mechanical resistance and protection 

from radiation. 

It consists of a “crimped metal box” containing cylindrical 

lead shielding, whose thickness varies from 5 to 35 mm, 

and an absorbent sponge. The shielding is kept in position 

inside the box by a mould of expanded polystyrene. The 

box is fixed inside cardboard packaging. The weight of 

the packaging varies from 0.5 to 10 kg. 

2. WHEN TO ORDER ? 

Please, refer to our « PRODUCTION CALENDAR » and 

remember that orders should arrive at the customer 

service at least two working days before production dates 

of all items concerned. 

Production Calendars are available online at: 

www.iba.worldwide.com 

3. WHERE TO ORDER ? 

In countries where we have no local representative, orders 

should be sent to : 

CIS bio international 

B.P. 32 

91192 Gif-sur-Yvette Cedex - FRANCE 

Telefax : 33 1 69 85 75 21 or 33 1 69 85 72 89 

Enquiries should be sent to : 


B.P. 32 

91192 Gif-sur-Yvette Cedex - FRANCE 

Telefax : 33 1 69 85 75 16

Scientific and technical information 

QUALITY CONTROL 

1. DEFINITIONS 

RADIOPHARMACEUTICAL PREPARATION 

(Directive 2004/27/EC amending Directive 2001/83/EC) 

Radiopharmaceutical 

Any medicinal product which, when ready for use, contains 

one or more radionuclides (radioactive isotopes) included 

for a medicinal purpose. 

Radionuclide generator 

Any system incorporating a fixed parent radionuclide 

from which is produced a daughter radionuclide which is 

to be obtained by elution or by any other method and 

used in a radiopharmaceutical. 

Kit 

Any preparation to be reconstituted or combined with 

radionuclides in the final radiopharmaceutical, usually 

prior to its administration. 

Radionuclide precursor 

Any other radionuclide produced for the radiolabelling 

of another substance prior to administration. 

RADIOCHEMICAL PREPARATION : 

The designation radiochemical preparation refers to a 

chemical product including one or more radiochemical 

preparations. 

Must not be injected in human. 

2. PRESENTATION 


Products are generally presented in vials (penicillin type) 

of 15 ml. 

Some products appear in 

• gelatin capsules 

• unidose plastic syringes, ready to use 

• generators : chromatography columns allowing the 

elution of short half-life radionuclides. 

Each package has a label showing the name of the 

product, the radioactive concentration, the specific 

radioactivity at a given date, the volume, the lot number, 

the expiry date and the conditions of storage. It contains 

also a package leaflet to read before using the product. 

RADIOCHEMICAL PREPARATION 

Products are generally presented in vials (penicillin type) 

of 2, 5, 10 and 30 ml. Some of them are packaged in 

sealed ampoules. 

Each package has one or two labels showing : the nature 

of the product, the radioactive concentration at a given 

date, the volume and the lot number. 

A red symbol indicates the radioactive character of the 

product. 

3. QUALITY CONTROL 


The manufacturing and distribution of radiopharmaceutical 

preparations (1) must respond to official standards, or in 

default, to protocols established in agreement with the 

competent authorities. The standards, which are rendered 

obligatory, are published in the pharmacopoeia (French, 

European, British pharmacopoeia, Pharmacopoeia of the 

USA, etc.) 

(1) Acceptance put in concrete form by the the opening authorization of 

pharmaceutical branch CIS bio international. 

According to these documents, the establishment of a 

quality control of the radiopharmaceutical preparations 

seems to be relatively easy. In fact, if the general methods 

of manufacturing, distribution and control are effectively 

described, all the radiopharmaceutical preparations are 

not included in monographs. 

Moreover, as the various pharmacopoeia do not always 

prescribe the same methods or the same standards, it is 

necessary to render them compatible. All these facts 

explain the difficulty to imagine a control system which 

takes into consideration the whole international statutory 

restraints. 

The quality control of the radiopharmaceutical 

preparation is effected at three levels : 

RAW MATERIAL CONTROL 

All the raw materials entering the manufacturing of the 

radiopharmaceutical products are stored and analysed 

before use following the rules of Quality Assurance. 

The delivery system used allows immediate crosschecking, 

in case of anomaly both in production and in 

the finished product. 



Scientific and technical information 

(continued) 

QUALITY CONTROL 

CONTROL OF THE MANUFACTURING 

PROCESSES 

The manufacturing of radiopharmaceutical preparations 

imperatively requires the respect of Good Manufacturing 

Practices describing the premises, the qualification of 

the manufacturing and control employees, and the 

adjustment of the materials used to the considered 

operations. 

The verification of the respect of these rules is effected 

by the Quality Assurance which uses two inner 

characteristics : the impartiality towards the producer 

and the availability of a suitable analytic procedure. 

CONTROL OF THE FINISHED PRODUCTS 

Systematic control of the raw materials and respect of the 

manufacturing procedures assure a quality guarantee 

which must be confirmed by the control of the finished 

product. 

There are 3 types of controls of the finished products : 

• Radiometrological controls allowing the 

identification of the radionuclides (in particular with g 

spectrometry), the measuring of radioactivity which 

ensures the radioactive concentration and the specific 

radioactivity. 

• Physical and chemical controls : 

The dosage of the active ingredients, the analysis of the 

radionuclidic and of the radiochemical purity, the 

measuring of the pH and the osmotic pressure demand 

various methods such as potentiometry, chromatography, 

electrophoresis, etc. 

• Biological controls : 

The injectable aqueous or colloidal solutions are, 

according to the monographs of the various 

Pharmacopoeia, submitted to controls of sterility, absence 

of abnormal toxicity, submitted to controls of sterility, 

bacterial endotoxin concentration and absence of 

abnormal toxicity. 

Besides, the quantitative analysis of the biodistribution of 

some radiopharmaceutical preparations is performed in 

animals. 


RADIOCHEMICAL PREPARATION 

The radiochemical preparations are submitted to certain 

controls at various levels of their production. 

There are 2 types of control : 

• Radiometrological controls allowing the 

identification of the radionuclides (in particular with g 

spectrometry), the measuring of radioactivity which 

ensures the radioactive concentration. 

• Physical and chemical controls allowing the 

determination of the chemical purity of the radioactive 

solutions delivered. 

Radiochemical preparations must not be administered 

to human. 

4. STORAGE 

The decomposition of the radiopharmaceutical 

preparations under the influence of their own radiation is 

a general phenomenon : in some cases it may shorten the 

duration of use. 

It is recommended 

• to maintain the products, as soon as they arrive, at a 

temperature suitable with their physical properties (the 

particular conditions of storage are notified on the label). 

• to use them as rapidly as possible, the expiry date 

is mentioned on each radiopharmaceutical preparation.

Units 

Each radionuclide is characterized : 

- by an unvarying period expressed in time unit 

- by the nature and the energy of the radiation(s) 

This energy is expressed in electronvolts (eV), 

kiloelectronvolts (keV), megaelectronvolts (MeV). 

The radioactivity (activity) of a preparation is defined by 

the amount of desintegrations or nuclear transformations 

occuring in this preparation per unit of time. 

The quantities of radioactivity in the International System 

(IS) are expressed in becquerel (Bq), corresponding to 

one nuclear transformation per second (dps = 

disintegration per second). 

The quantities of radioactivity may also be expressed in 

curie (Ci), the curie corresponding to 3.7 x 1010 

disintegrations per second, in millicurie, microcurie, or 

in nanocurie. 

The following factors make the conversion easier between 

the 2 unit systems : 

Becquerel in Curie: 1 Bq = 27.027 pCi = 1 dps 

1 Becquerel (Bq) = 27.027 Picocurie (pCi) 

1 Kilobecquerel (kBq) = 27.027 Nanocurie (nCi) 

1 Megabecquerel (MBq)= 27.027 Microcurie (µCi) 

1 Gigabecquerel (GBq) = 27.027 Millicurie (mCi) 

1 Terabecquerel (TBq) = 27.027 Curie (Ci) 

Curie in Becquerel: 1 Ci = 3.7 x 1010 Bq 

1 Nanocurie (nCi) = 37 Becquerel (Bq) 

1 Microcurie (µCi) = 37 Kilobecquerel (kBq) 

1 Millicurie (mCi) = 37 Megabecquerel (MBq) 

1 Curie (Ci) = 37 Gigabecquerel (GBq) 

1 Decacurie (daCi) = 0.37 Terabecquerel (TBq) 

Rad in Gray: 1 Rad/mCi = 0.27 mGy/MBq 

1 Millirad (mrad) = 10 Microgray (µGy) 

1 Rad = 10 Milligray (mGy) 

1 Rad = 1 Centigray (cGy) 

Gray in Rad: 

1 Microgray (µGy) = 0.1 Millirad (mrad) 

1 Milligray (mGy) = 100 Millirad (mrad) 

1 Centigray (cGy) = 1 Rad 

1 Gray (Gy) = 100 Rad 

Rem in Sievert : 

1 Millirem (mrem) = 10 Microsievert (µSv) 

1 Rem = 10 Millisievert (mSv) 

1 Rem = 1 Centisievert (cSv) 

Sievert in Rem : 

1 Microsievert (µSv) = 0.1 Millirem (mrem) 

1 Millisievert (mSv) = 100 Millirem (mrem) 

1 Centisievert (cSv) = 1 Rem 

1 Sievert (Sv) = 100 Rem 

CONVERSION TABLE FROM BECQUERELS 

INTO CURIES 

kBq 

MBq 

GBq 

3.7 

7.4 

9.25 

11.1 

14.8 

18.5 

37 

74 

92.5 

111 

148 

185 

222 

259 

296 

333 

370 

444 

µCi 

mCi 

Ci 

0.1 

0.2 

0.25 

0.3 

0.4 

0.5 

1 

2 

2.5 

3 

4 

5 

6 

7 

8 

9 

10 

12 

MBq 

GBq 

TBq 

1.11 

1.48 

1.85 

2.22 

2.59 

2.96 

3.33 

3.7 

4.62 

5.55 

7.4 

9.25 

11.1 

14.8 

18.5 

22.2 

25.9 

27.75 

29.6 

33.3 

37 

µCi 

mCi 

Ci 

30 

40 

50 

60 

70 

80 

90 

100 

125 

150 

200 

250 

300 

400 

500 

600 

700 

750 

800 

900 

1000 



Definitions (*) 

RADIONUCLIDIC PURITY 

The ratio, expressed as a percentage, of the radioactivity 

of the radionuclide concerned to the total radioactivity of 

the radiopharmaceutical preparation. The relevant 

radionuclidic impurities are listed with their limits in the 

individual monographs. 

RADIOCHEMICAL PURITY 

The ratio, expressed as a percentage, of the radioactivity 

of the radionuclide concerned which is present in the 

radiopharmaceutical preparation in the stated chemical 

form, to the total radioactivity of that radionuclide present 

in the radiopharmaceutical preparation. The relevant 

radiochemical impurities are listed with their limits in the 

individual monographs. 

CHEMICAL PURITY 

In monographs on radiopharmaceutical preparations 

chemical purity is controlled by specifying limits on 

chemical impurities. 

(*) Refer to the European Pharmacopoeia, current edition, Monograph 

“Radiopharmaceutical preparations”. 


ISOTOPIC CARRIER 

A stable isotope of the element concerned either present 

or added to the radioactive preparation in the same 

chemical form as that in which the radionuclide is present. 

SPECIFIC RADIOACTIVITY 

The radioactivity of a radionuclide per unit mass of the 

element or of the chemical form concerned. 

RADIOACTIVE CONCENTRATION 

The radioactivity of a radionuclide per unit volume.

Nuclides index 

Energies of main radiations emitted by the radionuclides used as radiopharmaceuticals. 

Radionuclides Half life 

Decay Emitted Energy 

Modes Radiations (Rev) 

% Intensity 

ERBIUM-169 169 Er 9.3 d � - e - 373 max 42 

351 max 58 

e - C 6-7 33.4 

8 8.4 

� 8.4 0.2 

FLUORINE-18 18 F 1.83 h � + e + 633 max 96.6 

(average 250) 

EC 3.1 

� � annihilation 511 96.9 

GALLIUM-67 67 Ga 3.25 d EC 100% 

� 912 3.1 

932 35.4 

185 22 

209 2.4 

300 16.5 

393 4.5 

IODINE-123 123 I 13.2 h EC 100% 

e - 127 13.6 

154 1.77 

158 0.43 

22-32 12.4 

2.3-4.8 98 

� 159 83.3 

529 1.4 

X K 27 70 

31 16 

X L 3.3-4.9 7.8 

IODINE-125 125 I 59.9 d EC 100% 

� 34.8 6.7 

e - 22-31 20.8 

34.4 2.4 

X k 27-32 139 

4-5 13 

IODINE-131 131 I 8.02 d � - e - 248 max 2.1 

334 max 7.3 

606 max 89.5 

e - 46 3.5 

� 80 2.6 

284 6 

364 81.3 

637 7.2 

722 1 



Nuclides index 

(continued) 

Radionuclides Half life 


Decay Emitted Energy 

Modes Radiations (Rev) 

% Intensity 

RHENIUM-186 186 Re 3.77 d � - e - 1076 max 71 

939 max 7.3 

308 max 7.3 

EC 7.6 

� 123 0.6 

137 9.5 

e - 63 4.1 

e - 124-126 6 

e - 5-13 12 

X K 58-74 10.2 

X L 7-13 5.2 

SAMARIUM-153 153 Sm 46.3 h � - e - 640 max 30 

710 max 50 

810 max 20 

e - C 21 24 

55 41 

95 6 

� 41 49 

47 12 

103 29 

TECHNETIUM-99m 99m Tc6.02 h � � 140 89.3 

IC e - 119 8.7 

121-142 2.14 

2 99.1 

15-18 2 

X K 18-21 7.2 

THALLIUM-201 201 TI 3.05 d EC 100% 

e - 27-31 2.7 

52 7.4 

84 15 

� 135 2.6 

167 9.8 

X K 69-83 95 

YTTRIUM-90 90 Y 2.67 d � - e - 2284 max 99.98% 

average 939 

average 523 0.02 

average 188 

Radiations used for a medical purpose 

EC : electron capture 

IC : internal conversion electrons

Radioactive decay table 

Hours Days 

Tc - 99m I - 123 Sm - 153 Y - 90 Mo - 99 

T1/2 = 6.02 h T1/2 = 13.2 h T1/2 = 46.3 h T1/2 = 64.1 h T1/2 = 66.2 h 

-168 -7 6.149 5.805 

-156 5.401 5.119 

-144 -6 4.744 4.515 

-132 4.167 3.982 

-120 -5 3.660 3.512 

-102 3.012 2.909 

-96 -4 4.209 2.823 2.732 

-84 3.517 2.480 2.409 

-72 -3 2.938 2.178 2.125 

-60 2.455 1.913 1.874 

-48 -2 2.052 1.680 1.653 

-36 1.714 1.476 1.458 

-24 -1 1.432 1.296 1.286 

-12 3.999 1.877 1.197 1.139 1.134 

-8 2.519 1.521 1.127 1.090 1.087 

-4 1.587 1.233 1.062 1.044 1.043 

-3 1.414 1.170 1.046 1.033 1.032 

-2 1.260 1.111 1.030 1.022 1.021 

-1 1.122 1.054 1.015 1.011 1.011 

Calibration 1 1 1 1 1 

1 0.891 0.949 0.985 0.989 0.990 

2 0.794 0.900 0.971 0.979 0.979 

3 0.707 0.854 0.956 0.968 0.969 

4 0.630 0.811 0.942 0.958 0.959 

5 0.561 0.769 0.928 0.947 0.949 

6 0.500 0.730 0.914 0.937 0.939 

7 0.446 0.693 0.901 0.927 0.929 

8 0.397 0.657 0.887 0.917 0.920 

9 0.354 0.624 0.874 0.907 0.910 

10 0.315 0.592 0.861 0.898 0.901 

12 0.250 0.533 0.836 0.878 0.882 

14 0.480 0.811 0.860 0.864 

16 0.432 0.787 0.841 0.846 

20 0.350 0.741 0.806 0.811 

24 1 0.284 0.698 0.771 0.778 

36 0.151 0.583 0.678 0.686 

48 2 0.081 0.487 0.595 0.605 

60 0.043 0.407 0.523 0.534 

72 3 0.340 0.459 0.471 

84 0.403 0.415 

96 4 0.354 0.366 

108 0.311 0.323 

120 5 0.273 0.285 

144 6 0.211 0.221 

168 7 0.163 0.172 




(continued) 


Hours Days Tl - 201 Ga - 67 Re - 186 

T1/2 = 3.05 d T1/2 = 3.26 d T1/2 = 3.77 d 

-168 -7 

-156 4.380 3.983 3.303 

-144 -6 3.909 3.582 3.013 

-132 3.489 3.220 2.748 

-120 -5 3.114 2.895 2.507 

-102 2.779 2.603 2.248 

-96 -4 2.481 2.340 2.086 

-84 2.214 2.104 1.903 

-72 -3 1.977 1.892 1.736 

-60 1.764 1.702 1.583 

-48 -2 1.575 1.530 1.444 

-36 1.406 1.376 1.317 

-24 -1 1.255 1.237 1.202 

-12 1.120 1.112 1.096 

-8 

-4 

-3 

-2 

-1 

Calibration 1 1 1 

1 

2 

3 

4 

5 

6 

7 

8 

9 

10 

12 0.893 0.899 0.912 

14 

16 

20 

24 1 0.797 0.808 0.832 

36 0.712 0.727 0.759 

48 2 0.635 0.654 0.692 

60 0.566 0.588 0.632 

72 3 0.506 0.528 0.576 

84 0.452 0.475 0.526 

96 4 0.403 0.427 0.479 

108 0.360 0.384 0.437 

120 5 0.321 0.345 0.399 

144 6 0.256 0.279 0.332 

168 7 0.204 0.226 0.276 

192 8 0.162 0.182 0.230


(continued) 

Hours Days 

I - 131 Er - 169 I - 125 

T1/2 = 8.02 d T1/2 = 9.40 d T1/2 = 59.9 d 

-180 -7.5 2.373 

-168 -7 1.831 1.084 

-156 -6.5 1.371 1.615 

-144 -6 1.679 1.556 

-132 -5.5 1.608 1.500 

-120 -5 1.540 1.446 1.060 

-108 -4.5 1.475 1.393 

-96 -4 1.413 1.343 

-84 -3.5 1.353 1.294 

-72 -3 1.296 1.248 1.035 

-60 -2.5 1.241 1.202 

-48 -2 1.189 1.159 

-36 -1.5 1.138 1.117 

-24 -1 1.090 1.077 1.012 

-12 -0.5 1.044 1.038 

Calibration 1 1 1 

12 0.5 0.958 0.964 

24 1 0.917 0.929 0.988 

36 1.5 0.878 0.895 

48 2 0.841 0.863 

60 2.5 0.806 0.832 

72 3 0.772 0.802 0.966 

84 3.5 0.739 0.773 

96 4 0.708 0.745 

108 4.5 0.678 0.718 

120 5 0.649 0.692 0.944 

132 5.5 0.622 0.667 

144 6 0.595 0.643 

156 6.5 0.570 0.619 

180 7 0.546 0.597 0.922 

204 8 0.501 0.554 

228 9 0.460 0.515 0.901 

252 10 0.421 0.478 0.891 

276 11 0.387 0.444 

300 12 0.355 0.413 0.870 

324 14 0.298 0.356 

348 15 0.274 0.331 0.841 

20 0.178 0.229 0.793 

25 0.158 0.749 

30 0.707 

40 0.630 

45 0.594 

50 0.561 

55 0.529 

60 0.499 




Locations and contacts 

IBA Europe 

Europe Head office 

Mail address: 

IBA 


BP 32 

91192 Gif-sur-Yvette Cedex, 

France 

+ 33 1 69 85 73 22 

Visitor address: 


Centre CEA - RN306 

91400 Saclay, France 

Europe Subsidiaries 

UK and Ireland offices 

IBA UK Ltd. 

Unit 19, Old Portsmouth 

Rd GU3 1LU Peasmarsh 

Guilford, UK 

P + 44 1 483 301 638 

sharon.edwards@iba-group.com 

Benelux offices 

IBA Benelux 

Chemin du Cyclotron, 3 

1348 Louvain-la-Neuve 

Belgium 

P + 32 10 20 12 81 

laurence.debacker@iba-group.com 

France offices 

IBA France 


BP 32 

91192 Gif-sur-Yvette Cedex, 

France 

P +33 1 69 85 73 35 

brigitte.ouille@iba-group.com 

www.iba-molecular.com 

Spain and Portugal offices 

IBA Spain, SA 

Avda. Dr. Severo Ochoa, 29 

28100 Alcobendas (Madrid) 

P + 34 914 905 648 

lola.sanchez@iba-group.com 

Germany and Eastern Europe offices 

IBA Germany 

Cis bio GmbH 

Alt- Moabit 91 d 

1059 Berlin, Germany 

P + 49 30 8009 305 0 

info@cisbio.de 

www.iba-molecular.de 

Italy offices 

IBA Italy 

CIS bio SpA 

Piazza della Repubblica, 5 

20121 Milano, Italy 

P + 39 02362632 

mariagloria.trigari@iba-group.com 

IBA US Head office 

IBA Northen America 

21 000 Atlantic Blvd, Ste 730 

Dulles, VA 20166, USA 

P +1 703 787 7900 

IBA Asia Head office 

IBA Asia 

D -131 Sector 63 

Noida, U.P 201301, India 

nicolas.bruiez@iba-group.com 

Phone: +91 120 4335017 

Fax: +91 120 4335017 Ext. 21 

For other locations 



International Department 

BP 32 - 91192 Gif-sur-Yvette Cedex, 

France 

P +33 1 69 85 73 64 

nicolas.cherrier@iba-group.com 

www.iba-molecular.com 


Printed in FRANCE - DELTA GRAPHIQUE SERVICE - September 2010 - P-D-10-235-v9 

PRODUCT 

CATALOGUE 


Member of IBA group 

B.P. 32 - 91192 Gif-sur-Yvette Cedex 

France 

Tel : +33 1 69 85 75 70 

Fax : +33 1 69 85 72 09 

Headquarters 


Avenue Albert Einstein, 4 

1348 Louvain-la-Neuve 

Belgium 

IBA delivers solutions of unprecedented 

precision in the fields of cancer diagnosis and 

therapy. The company also offers sterilization 

and ionization solutions to improve the hygiene 

and safety of everyday life. 

www.iba-worldwide.com

IBA catalog GB int60p 10 v9 - IBA Molecular

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?